Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database

Fig. 4

1 L to 2 L treatment flow in patients with mRCC in the Truven Health MarketScan databases. Possible reasons for patients not receiving 2 L treatment include still being on 1 L treatment, no requirement for 2 L treatment, refusal of treatment and death, although these cannot be reliably obtained from the claims database

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us